SIASUN(SZ:300024) 3 6 Ke·2025-08-17 14:08Core Viewpoint - Ruixin Medical is committed to developing an all-automatic AI vascular interventional surgical robot to enhance early diagnosis and precise treatment of cardiovascular diseases, aiming to create a closed-loop diagnostic and treatment system [1][3]. Company Developments - The all-automatic AI vascular interventional surgical robot is expected to complete animal surgeries using AI automation in the second half of this year, following prototype production and simulation experiments [3]. - The robot aims to assist in simple and repetitive surgical procedures under the supervision of doctors, while providing enhanced support for more challenging surgeries [3][4]. Industry Challenges - The cardiovascular treatment field faces three main challenges: heavy physical burden on doctors due to lead aprons, variability in manual operations leading to training difficulties for younger doctors, and uneven distribution of medical resources across the country [3][4]. Technological Integration - Ruixin Medical's robot integrates a tri-party collaboration among doctors, intelligent systems, and execution terminals, allowing for natural language interaction and automated surgical operations [4]. - The short-term goals include reducing radiation exposure, alleviating the burden of lead aprons, lowering repetitive tasks, shortening training periods, standardizing surgical quality, and supporting remote medical services [4]. Regulatory Environment - The launch of the robot coincides with the National Medical Products Administration's new measures to support high-end medical device innovation, marking a significant step towards the "fully automatic" intelligent era in vascular intervention [5]. Expert Insights - Experts agree that the integration of AI and fully automatic vascular interventional robots represents a major trend for the future, emphasizing the importance of overcoming challenges to lead in this innovative field [5].